Sodium-glucose cotransporter 2 inhibitors as an add-on therapy to insulin for type 1 diabetes mellitus: Meta-analysis of randomized controlled trials.

ABSTRACT:

Aims

The aim was to systematically review the efficacy and safety of sodium-glucose cotransporter inhibitor (SGLT2i) as an adjunct to insulin at different follow-up durations in randomized, double-blind clinical trials in patients with type 1 diabetes.

Methods

We conducted a search on Medline, Embase, and the Cochrane Library for relevant studies published before May 2020. According to the duration of follow-up, the subgroup analysis included four periods: 1-4, 12-18, 24-26, and 52 weeks. In the five trials included both 24-26 and 52 weeks of follow-up, we compared the efficacy by the placebo-subtracted difference and changes in SGLT2i groups.

Results

Fifteen trials including 7109 participants were analyzed. The combination of SGLT2i and insulin improved hemoglobin A1

SUBMITTER: Rao L 

PROVIDER: S-EPMC8187227 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature